GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » COGS-to-Revenue

Zura Bio (Zura Bio) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio COGS-to-Revenue?

Zura Bio's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Zura Bio's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Zura Bio's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Zura Bio COGS-to-Revenue Historical Data

The historical data trend for Zura Bio's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio COGS-to-Revenue Chart

Zura Bio Annual Data
Trend Dec21 Mar22 Dec23
COGS-to-Revenue
- - -

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zura Bio COGS-to-Revenue Calculation

Zura Bio's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Zura Bio's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zura Bio  (NAS:ZURA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Zura Bio's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Zura Bio COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zura Bio's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio (Zura Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » COGS-to-Revenue
Comparable Companies
HUMA ATAI ARQT LCTX EPIX RENB AEON XOMA FATE IMRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
94E:Germany
Address
4225 Executive Square, Suite 600, La Jolla, CA, USA, 92037
Website
https://www.zurabio.com
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Steven J Schoch director 2748 BUSH STREET, SAN FRANCISCO CA 94115
Preston Klassen officer: President and COO 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Cabell officer: EVP and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105